BioMarin Pharmaceutical Inc. announced the closing of an $850 million private placement of 5.500% Senior Notes due 2026. The proceeds, along with borrowings from new senior secured term loan facilitie...

BioMarin Pharmaceutical Inc. announced the closing of a $850 million private placement of 5.500% Senior Notes due 2026. The proceeds, along with borrowings from new senior secured term loan facilities...

Alnylam Pharmaceuticals filed an 8-K on February 12, 2026, announcing its financial results for the quarter ended December 31, 2025.

Teva Pharmaceutical Industries Ltd. filed an 8-K on January 28, 2026, announcing its financial results for the full year and fourth quarter of 2025. The filing includes a press release (Exhibit 99.

Halozyme Therapeutics (HALO) filed an 8-K on January 28, 2026, reporting preliminary, unaudited financial estimates for the year ended December 31, 2025, and providing updated financial guidance for 2...

Amgen filed an 8-K on February 3, 2026, reporting its unaudited results of operations for the fourth quarter and full year 2025.

Piper Sandler Companies (PIPR) announced the appointment of Stuart M. Essig to its Board of Directors, effective February 4, 2026.

Eli Lilly and Company filed an 8-K on February 4, 2026, reporting its financial results for the quarter and year ended December 31, 2025. The filing includes a press release (Exhibit 99.

BioMarin Pharmaceutical Inc. (BMRN) announced the pricing of a $850 million private offering of 5.500% senior unsecured notes due 2034.

Regeneron Pharmaceuticals announced its fourth quarter and full year 2025 financial results, showcasing revenue growth driven by Dupixent and EYLEA HD. Q4 revenues increased 3% to $3.